Synonyms: CPI-000818 | CPI-818 | CPI818 | example 44 [WO2018089261]
Compound class:
Synthetic organic
Comment: Soquelitinib (CPI-818) is an oral inhibitor of interleukin-2-inducible T cell kinase (ITK).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
CPI-818 is a clinical candidate for the treatment of advanced T-cell lymphoma. The FDA granted orphan designation in Feb. 2024 for this indication. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | Phase 1 Interventional | Corvus Pharmaceuticals, Inc. |